We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 11,988.00
Bid: 12,016.00
Ask: 12,020.00
Change: -38.00 (-0.32%)
Spread: 4.00 (0.033%)
Open: 12,070.00
High: 12,144.00
Low: 11,882.00
Prev. Close: 12,026.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET OPEN: Stocks Start Lower Ahead Of Trump Press Conference

Fri, 29th May 2020 08:51

(Alliance News) - Stock prices in London opened in the red on Friday, as worsening US–China relations overshadow optimism from the easing of coronavirus lockdowns across the globe.

The FTSE 100 index was down 36.50 points, or 0.6%, at 6,182.29 on Friday. Since the week began, the blue-chip index is up 2.8%, though it remains down 18% so far in 2020.

The mid-cap FTSE 250 index was down 58.89 points, or 0.3%, at 17,279.59, and the AIM All-Share index was down 0.2% at 873.60.

The Cboe UK 100 index was 0.8% lower at 10,446.43. The Cboe 250 was down 0.4% at 14,781.40, and the Cboe Small Companies down 0.1% at 12,120.78.

In mainland Europe, the CAC 40 in Paris was down 0.8%, while the DAX 30 in Frankfurt was down 1.1%.

"Risk-off is dominating as investors look ahead to Trump's response, provoked by China's crackdown on civil liberties in Hong Kong, Asia's financial hub," said City Index analyst Fiona Cincotta.

Trump said he will give a press conference Friday on China amid rising US-Chinese tensions over Hong Kong and the coronavirus fallout.

Trump told reporters of his plan for the press conference at an Oval Office meeting on Thursday, but gave no specific details of what he would be announcing.

Fears that China will use a new law to end Hong Kong's freedom as a semi-autonomous territory have prompted expectations that Trump plans to hit back, possibly signalling a wider economic confrontation between the two superpowers.

Washington and Beijing are already clashing over responsibility for the extent of the coronavirus pandemic, which originated in China but has caused devastation in the US. The US recorded 1,297 coronavirus deaths on Thursday, bringing its total to 101,573 since the global pandemic began, according to a tally kept by Johns Hopkins University.

The country has officially logged 1.7 million cases of the virus, far more than any other nation, the tracker kept by the Baltimore-based university showed. Trump blames that on China, although his domestic critics accuse him of mismanagement.

"The fear is that the US–China spat could hamper a fragile economic recovery from the coronavirus crisis," added Cincotta.

The Hang Seng index in Hong Kong closed down 0.7% on Friday. Elsewhere in China, the Shanghai Composite finished up 0.2%. In Japan, Tokyo's Nikkei 225 index closed down 0.2%.

On the London Stock Exchange, AstraZeneca was among the best performers in the blue-chip index, up 1.3%, after its phase 3 Adaura trial of Tagrisso in early-stage cell lung cancer found that the drug reduced the risk of disease recurrence or death by around 80%.

The detailed results were from a trial of Tagrisso, the brand name for osimertinib, after surgery in patients with "epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer after complete tumour resection with curative intent". EGFR mutations are associated with some lung cancers.

In the primary endpoint of disease-free survival in patients with stage 2 and 3A disease, treatment with Tagrisso reduced risk of disease recurrence or death by 83%. Disease-free survival in the overall trial population, covering stages 1B to 3A, found a 79% drop in the risk of disease recurrence or death.

At the two year mark, 89% of patients in the trial who had been treated with Tagrisso were still alive and disease free compared to a 53% figure in patients who were given a placebo.

Admiral Group was among the worst performers on Friday morning, down 1.6%, after Barclays cut the insurer to Equal Weight from Overweight.

Fresnillo was trading 1.5% lower after saying that it is responding to operational challenges caused by Covid-19 after a tough 2019. The Mexican gold miner said it has focused on responding to the Covid-19 over the past three months, implementing a range of safety measures across the business.

"Up to this point, we have had no officially confirmed Covid-19 cases originating from inside our operations," said Chair Alberto Bailleres. However, he noted that three colleagues were officially diagnosed from exposure outside.

Fresnillo also confirmed that the board and senior management took voluntary and temporary pay cuts to help the company get through this "unprecedented" situation.

Fresnillo said its operations are critical to the economies in which it operate, with mining now confirmed as an essential activity in Mexico.

"Operationally, 2019 was a more challenging year, as expected," said Bailleres.

Both silver and gold production fell from 2018 levels, due to lower-than-anticipated grades in its key mines. This also hurt Fresnillo's financial performance.

In the face of these operational challenges, the company said its response has been to increase the pace and scale of investments in a series of projects and take corrective actions to bring production back to acceptable levels in the short-term, and to achieve steady growth in future years.

"We are investing in infrastructure, plant and machinery including a state-of-the-art tunnel boring machine which is now being ramped up at Fresnillo - one of the first of its kind. We have also begun to define a new programme to control costs and increase productivity," said Bailleres.

Among the mid-caps, Provident Financial was the best performer, up 4.4% in early trade, after getting an upgrade from Jefferies to Buy from Hold.

B&M European Value Retail was the second-best performer in the FTSE 250 index, up 3.6%. B&M reported a strong end to the fourth quarter - which ran to March 28 - driven by exceptionally strong March performance in Grocery, with the B&M UK fascia like-for-like revenue up 6.6%.

Going forward, B&M said it experienced strong revenue growth in the first 8 weeks to May 23, with B&M UK fascia like-for-like revenue up 23%, driven by exceptionally strong Do It Yourself and Gardening categories, and despite a significant fall in customer count.

If DIY and Gardening categories are excluded, the B&M UK fascia like-for-like revenue over that 8 week period was up 10%.

"We have encountered exceptionally strong demand in our UK business over recent weeks. Customers have been coming to our stores much less frequently through the lockdown but their average spend has been much higher than normal," said Chief Executive Simon Arora.

"Clearly, there is also considerable uncertainty in relation to both the progression of Covid-19 and the economic outlook, and it is therefore hard to predict future trading levels," added Arora.

SIG was up 3.6% in the morning trading on Friday. The building products supplier announced plans to bring in a substantial new investor as part of an equity fundraise to deliver a new growth strategy, after swinging to a loss in 2019.

SIG reported a 9.0% decline in revenue in 2019 to GBP2.08 billion. On a like-for-like basis, sales declined by 7.6%.

SIG said its performance was hurt by market share losses in UK and Germany due to poor execution of transformation initiatives which, it believes, disconnected the business from its customers, suppliers and its front-line colleagues.

As a result, the company swung to pretax loss of GBP112.7 million in 2019 compared to GBP10.3 million profit a year prior.

SIG cut its dividend to 1.25 pence, having paid a 3.75p per share payout in 2018.

"The 2019 results, albeit in line with January guidance, are disappointing. However, the board has taken decisive action to address this performance. A new chief executive has been appointed and, this morning, we announced the appointment of a new chief financial officer," said Chair Andrew Allner.

SIG named Ian Ashton as permanent CFO and Simon King as a non-executive director, both with effect from the start of July.

Ashton replaces Kath Kearney-Croft, who had taken on the role of interim CFO back in February. Ashton will join SIG from Low & Bonar, where he has served as CFO.

Going forward, SIG said it has explored its wider funding options and is intending to raise GBP150 million in new equity in the coming weeks to strengthen its capital structure and enable the management team to deliver its new growth strategy. The equity raise will be led by US private equity firm Clayton, Dubilier & Rice, which will contribute up to GBP85 million and take an about 25% stake in SIG as a result.

In commodities, gold was quoted at USD1,721.98 an ounce early Friday, soft from USD1,722.65 late Thursday. Brent oil was at USD35.08 a barrel, up from USD34.45.

"Safe haven gold is building on gains from the previous session as tensions between the US and China mount, although the US dollar is slipping lower, decoupling from falling stocks," said City Index's Cincotta.

Against the yen, the dollar was trading at JPY107.19 early Friday in London, down from JPY107.60 late Thursday.

The pound was quoted at USD1.2350 early Friday, firm from USD1.2323 at the London equities close Thursday. The euro was at USD1.1100 early Friday, up from USD1.1067 late Thursday.

German retail sales slumped in April, the latest data from Destatis showed on Friday, with a separate release showing import prices also sank.

Retail sales were down 5.3% on a monthly basis and 6.5% annually in April, far steeper than falls of 4.0% and 1.2% recorded, respectively, for March.

Separately, the statistical body showed import prices were down 7.4% in April year-on-year, the sharpest fall recorded since 2009. In March, prices had fallen 5.5%.

The economic events calendar on Friday has eurozone inflation figures at 1000 BST. In the London afternoon, there are US personal consumption expenditure index numbers at 1330 BST - the core reading is the US Federal Reserve's preferred gauge of inflation.

By Evelina Grecenko; evelinagrecenko@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
9 Feb 2024 09:15

LONDON BROKER RATINGS: Deutsche Bank cuts AstraZeneca to 'sell'

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning:

Read more
9 Feb 2024 07:51

LONDON BRIEFING: Barclays buys Tesco's retail banking business

(Alliance News) - Stocks in London are called to open higher on Friday, closing off a busy corporate week.

Read more
8 Feb 2024 17:00

LONDON MARKET CLOSE: Softer earnings weigh on underperforming FTSE 100

(Alliance News) - London's FTSE 100 ended lower on Thursday, with mixed corporate updates keeping a lid on enthusiasm, while in New York the S&P 500 has the 5,000 point mark in touching distance.

Read more
8 Feb 2024 14:42

London close: Stocks slip as US jobless claims fall

(Sharecast News) - London markets experienced a downturn in trading on Thursday, with stocks relinquishing earlier gains as investors processed a decrease in jobless claims in the United States.

Read more
8 Feb 2024 12:08

LONDON MARKET MIDDAY: DS Smith surges on takeover approach from Mondi

(Alliance News) - Stock prices in London were mixed at midday Thursday, as markets struggled to find direction amid a mixed wave of corporate updates and earnings.

Read more
8 Feb 2024 08:59

LONDON MARKET OPEN: Unilever up on buyback; BAT ups dividend

(Alliance News) - THE FTSE 100 in London opened slightly higher on Thursday, with earnings from British American Tobacco and Unilever boosting the index.

Read more
8 Feb 2024 08:44

TOP NEWS: AstraZeneca confident after 2023 profit more than doubles

(Alliance News) - AstraZeneca PLC on Thursday said it expects another year of strong growth after reporting pretax profit in 2023 more than doubled.

Read more
8 Feb 2024 07:58

AstraZeneca shares slip as Q4 profits miss forecasts

(Sharecast News) - Biopharma titan AstraZeneca delivered a 6% increase in sales in 2023 despite a $3.7bn decline in Covid-19 medicines revenues, as it guided to a strong pick-up in growth this year - though profits came in slightly under analysts' forecasts.

Read more
8 Feb 2024 07:50

LONDON BRIEFING: Unilever sets new buyback; Astra profit surges

(Alliance News) - Stocks in London are called to open slightly higher on Thursday, as investors eye a busy day of earnings.

Read more
2 Feb 2024 08:38

AstraZeneca celebrates latest successful trial of acoramidis in Japan

(Alliance News) - AstraZeneca PLC on Friday said positive results from a Phase 3 trial of acoramidis are consistent with global findings, bring the drug closer to regulatory submission in Japan.

Read more
2 Feb 2024 06:22

TOP NEWS: US sends drugmakers initial offers in Medicare price talks

(Alliance News) - The US government said it was making initial offers to drugmakers Thursday as part of Medicare negotiations meant to lower the prices many older Americans would pay for 10 medicines.

Read more
1 Feb 2024 15:52

UK earnings, trading statements calendar - next 7 days

Friday 2 February 
YouGov PLCTrading Statement
Monday 5 February 
Home REIT PLCTrading Statement
Porvair PLCFull Year Results
Trident Royalties PLCTrading Statement
Vodafone Group PLCTrading Statement
Tuesday 6 February 
Alumasc Group PLCHalf Year Results
BP PLCFull Year Results
Filtronic PLCHalf Year Results
Mattioli Woods PLCHalf Year Results
Renishaw PLCHalf Year Results
Virgin Money UK PLCTrading Statement
Wednesday 7 February 
Ashmore Group PLCHalf Year Results
Barratt Developments PLCHalf Year Results
HydrogenOne Capital Growth PLCTrading Statement
Phoenix Spree Deutschland LtdTrading Statement
PZ Cussons PLCHalf Year Results
Smurfit Kappa Group PLCFull Year Results
UK Commercial Property REIT LtdTrading Statement
Thursday 8 February 
Anglo American PLCTrading Statement
AstraZeneca PLCFull Year Results
British American Tobacco PLCFull Year Results
Compass Group PLCTrading Statement
Redrow PLCHalf Year Results
SSE PLCTrading Statement
Unilever PLCFull Year Results
  
Comments and questions to newsroom@alliancenews.com
  
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
29 Jan 2024 08:19

TOP NEWS: AstraZeneca, Daiichi's Enhertu granted priority review in US

(Alliance News) - AstraZeneca PLC on Monday said its cancer drug conjugate received priority review by the Food & Drug Administration in the US for patients with metastatic HER2-positive solid tumours.

Read more
22 Jan 2024 11:45

BioNTech challenges AstraZeneca with breast cancer precision drug trial

FRANKFURT, Jan 22 (Reuters) - BioNTech and its partner Duality Biologics said on Monday they initiated a late-stage trial testing their precision drug against a certain type of breast cancer, taking on a rival partnership between AstraZeneca and Daiichi Sankyo.

Read more
19 Jan 2024 09:28

TOP NEWS: AstraZeneca's Voydeya receives approval in Japan for PNH

(Alliance News) - AstraZeneca PLC on Friday said its inhibitor Voydeya, also known as danicopan, received approval in Japan for adults with paroxysmal nocturnal haemoglobinuria, or PNH.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.